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Abstract: Hyperbaric oxygen (HBO) therapy has been reported to be beneficial for treating many
conditions of inflammation-associated bone loss. The aim of this work was to in vitro investigate
the effect of HBO in the course of osteogenesis of human Mesenchymal Stem Cells (MSCs) grown
in a simulated pro-inflammatory environment. Cells were cultured with osteogenic differentiation
factors in the presence or not of the pro-inflammatory cytokine Tumor Necrosis Factor-α (TNF-α),
and simultaneously exposed daily for 60 min, and up to 21 days, at 2,4 atmosphere absolute (ATA)
and 100% O2. To elucidate osteogenic differentiation-dependent effects, cells were additionally
pre-committed prior to treatments. Cell metabolic activity was evaluated by means of the MTT assay
and DNA content quantification, whereas osteogenic and vasculogenic differentiation was assessed
by quantification of extracellular calcium deposition and gene expression analysis. Metabolic activity
and osteogenic properties of cells did not differ between HBO, high pressure (HB) alone, or high
oxygen (HO) alone and control if cells were pre-differentiated to the osteogenic lineage. In contrast,
when treatments started contextually to the osteogenic differentiation of the cells, a significant reduction
in cell metabolic activity first, and in mineral deposition at later time points, were observed in the
HBO-treated group. Interestingly, TNF-α supplementation determined a significant improvement
in the osteogenic capacity of cells subjected to HBO, which was not observed in TNF-α-treated
cells exposed to HB or HO alone. This study suggests that exposure of osteogenic-differentiating
MSCs to HBO under in vitro simulated inflammatory conditions enhances differentiation towards the
osteogenic phenotype, providing evidence of the potential application of HBO in all those processes
requiring bone regeneration.
Keywords: adipose-derived stem cells; hyperbaric oxygen therapy; inflammation; osteogenic
differentiation; vasculogenic differentiation; bone regeneration
1. Introduction
Bone loss and subsequent repair are biological processes related to many pathological
conditions affecting bones, including fractures, osteoporosis, osteoarthritis, osteomyelitis, osteonecrosis,
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and tumors [1]. Current treatments are typically invasive and, depending on the bone-affecting disease,
they involve grafting, surgery, debridement, and/or pharmacotherapy [2]. Recently, hyperbaric oxygen
(HBO) has been proposed as an adjunctive therapy in the management of several conditions requiring
bone healing [3–6]. The HBO therapy is the noninvasive administration of 100% O2 at pressures greater
than one atmosphere absolute (ATA). Treatments usually involve pressurization between 1.5 and
3.0 ATA inside airtight chambers for periods between 60 and 120 min once or twice daily [7]. In this
way, it is possible to deliver a greatly increased supply of oxygen to tissues, which is advantageous for
fibroblasts proliferation, collagen fiber deposition, and formation of new blood vessels, thus accelerating
tissue repair and healing, and easing pain [8]. In addition, high-pressure oxygen can enhance the
viability and capacity of phagocytic cells, which are beneficial to the absorption and removal of necrotic
tissues, and reduction of local inflammation [9].
Inflammation also represents a crucial event in the process of bone repair, being the initial
inflammatory response necessary for the regeneration to progress [10]. In fact, inflammatory stimuli
determine the recruitment of Mesenchymal Stem Cells (MSCs), and direct their migration, proliferation
and differentiation into mature osteoblasts [11]. At the same time, MSCs modulate inflammatory cells
to promote resolution of pro-inflammatory activities, and reconstitution of normal tissue [12]. Tumor
Necrosis factor-α (TNF-α) is among the inflammatory mediators more significantly elevated after bone
injury [13]. Nevertheless, prolonged or chronic expression of these inflammatory molecules has negative
effects on bone, leading to increased bone resorption and suppressed bone formation [13]. A clear
example of bone loss determined by a chronic inflammatory state is represented by periodontitis. In this
multifactorial disease, levels of different inflammatory mediators, such as interleukin-1 (IL-1), IL-6,
prostaglandins, C-reactive protein, as well as TNF-α, are found elevated in patients’ serum [14]. In the
long term, this prolonged inflammatory condition causes the tooth’s supporting tissues, in particular
the alveolar bone, to be destroyed, leading to the final loss of the tooth. Several studies have evidenced a
positive correlation between periodontal disease and cardiovascular disease (CVD), including coronary
heart disease, stroke, and endothelial dysfunction [15,16]. In very recent works, numerous molecules
have been identified in serum and saliva of patients suffering from both periodontitis and CVD,
in particular high levels of endothelin-1 and asymmetric dimethylarginine, and low levels of vitamin
C and antioxidants, which can be used as novel biomarkers for predicting the development of these
different but related diseases [17–19].
In the light of these observations, the rationale of the current study was to determine whether HBO
or its individual constituents, elevated pressure or elevated oxygen, could influence different cellular
functions, and if these change depending on the inflammatory microenvironment in which the cells
reside. In detail, the aim of the present work was to analyze the direct effects of HBO on the metabolic
activity and on the osteogenic and vasculogenic differentiation properties of human Adipose-Derived
Stem Cells (hADSCs) grown in a simulated pro-inflammatory environment. MSCs isolated from
human adipose tissue samples share many properties with those harvested from bone marrow,
especially the same differentiation potential and a similar surface markers expression [20]. In addition,
hADSCs represent a source of several cytokines and soluble factors with angiogenic, antiapoptotic,
and antioxidative properties, and also act as modulators of the immune system, by inhibiting the
secretion of inflammatory cytokines while stimulating the production of those with anti-inflammatory
activity [21]. As of these properties and because these cells can be easily harvested in great amounts with
minimal donor-site morbidity and without ethical concerns, hADSCs have proved to be particularly
promising for bone repair and regeneration therapies [22].
In this study, the inflammatory environment was recreated in vitro by exposing hADSCs to the
pro-inflammatory cytokine TNF-α for all the duration of the osteogenic differentiation. Contextually,
cells were treated daily for 60 min, and up to 21 days, at 2,4 ATA and 100% O2. The influence of the
individual stimuli, high pressure or high oxygen, on stem cells functions was also explored. In order
to evaluate the effect of HBO during the osteogenic differentiation process, hADSCs were additionally
pre-exposed to osteogenic factors for 10 days before starting treatments. Then, cell metabolic activity
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was evaluated by means of the MTT assay and measurement of DNA content, whereas osteogenic
differentiation was assessed by quantification of extracellular calcium deposition after Alizarin Red
S (ARS) staining and gene expression analysis of selected osteogenic markers. Real-time PCR was
employed for additionally evaluating the expression of some vasculogenic markers. The results of our
work suggest that osteogenic-differentiating cells respond differently to pressure and oxygen signals,
in particular under an inflammatory environment. Notably, the combination of high pressure and
high oxygen seems to favor hADSCs osteogenesis during the prolonged inflammatory state, providing
evidence of the potential therapeutic use of HBO in all those physiological processes that require
bone regeneration.
2. Results
2.1. Effect of HBO on hADSCs Metabolic Activity
The MTT assay and quantification of DNA content were performed at selected time points over
a period of 21 days to compare the metabolic activity of hADSCs exposed to different pressure and
oxygen signals. As shown in Figure 1A, untreated cells showed an increase in proliferation up to
14 days of culture; then, these stopped to proliferate and reached the plateau phase at day 21. Compared
with the control group, daily HBO treatment determined a significant (p < 0.001) decrease in the rate of
hADSCs proliferation both at day 7 and day 14. In a similar way to HBO, cell metabolic activity was
significantly (p < 0.001) reduced in the HO-treated cultures at day 14. On the contrary, treatment with
high pressure alone did not induce any significant change in cell metabolic activity compared with
the control. In any case, at day 21, all the cell cultures reached confluence and no difference in cell
proliferation was noted between the treated and untreated groups. These trends were confirmed by
quantification of DNA content at the different culture time (Figure 1B).
Figure 1. Metabolic activity and proliferation of human Adipose-Derived Stem Cells (hADSCs)
after hyperbaric oxygen (HBO) treatment. (A) MTT assay and (B) quantification of DNA content
in hADSCs 1 day (d1), 7 days (d7), 14 days (d14), and 21 days (d21) after osteogenic differentiation
in Osteogenic Differentiation Medium (ODM) and hyperbaric oxygen (HBO), hyperbarism (HB),
or hyperoxia (HO) treatment. The control condition (CTRL) is represented by cells grown under
normoxia and normobarism. Data are shown as mean ± standard deviation (SD). * p < 0.05, *** and
$$$ p < 0.001 indicate statistically significant difference between the HBO- or HO-treated cells and the
control group, respectively.
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When the pro-inflammatory cytokine TNF-αwas added to the Osteogenic Differentiation Medium
(ODM) contextually to the beginning of treatments, the results of the MTT assay (Figure 2A) and DNA
content quantification (Figure 2B) revealed that hADSCs exposed to HBO, HB or HO had comparable
growth rates with respect to the control condition up to day 14. However, at day 21, a significant
reduction in cell metabolic activity was observed in all the three treated groups.
Figure 2. Metabolic activity and proliferation of hADSCs after HBO treatment in the presence of
inflammation. (A) MTT assay and (B) quantification of DNA content in hADSCs 1, 7, 14, and 21 days
after osteogenic differentiation in the presence of 10 ng/mL Tumor Necrosis factor-α (TNF-α) and
HBO, HB, or HO treatment. Data are shown as mean ± SD. In both graphs, # and $ p < 0.05 indicate
statistically significant difference between the HB- or HO-treated cells and control. ** p < 0.01 and
*** p < 0.001 indicate statistically significant difference between the HBO-treated cells and the control
group; ### p < 0.001 indicates statistically significant difference between the HB-treated cells and the
control group.
2.2. Effect of HBO on Extracellular Matrix Mineralization
Staining of calcium deposits in the extracellular matrix followed by quantification of extracted
ARS is reported in Figure 3. ARS accumulation in cells was detectable after 21 days of osteogenic
differentiation both in the control and in the HBO-, HB-, or HO-treated groups (Figure 3A). Nevertheless,
quantification of ARS stain by Cetylpyridinium Chloride (CPC) extraction revealed that levels of
calcium deposition were significantly lower for all the treated cultures compared with the untreated
control group (Figure 3B). Notably, a significant (p < 0.001) reduction in ARS quantification was
noticeable already at day 7 for the HB-treated cultures, and at day 14 for the HBO group.
ARS accumulation was visible at day 21 of osteogenic differentiation for all the tested conditions,
even when the cells were cultured in the presence of the pro-inflammatory cytokine TNF-α (Figure 4A).
Nevertheless, under in vitro simulated inflammatory conditions level of calcium deposition was
significantly (p < 0.001) higher in cells subjected to the HBO treatment compared to control (Figure 4B).
On the contrary, no differences were detected in the amount of mineral nodules formation between
treatments with elevated pressure or elevated oxygen alone and the control group at day 21. Compared
to control, extracellular calcium deposition in the HBO-treated group started to increase significantly
(p < 0.01) at 14 days of culture.
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Figure 3. Matrix mineralization in hADSCs after HBO treatment. (A) Alizarin Red S (ARS) staining
and (B) quantification of calcium deposits in hADSCs after d1, d7, d14, and d21 of culture in ODM
and HBO, HB, or HO treatment. Scale bars 100 µm. Data are shown as mean ± SD. ** p < 0.01 and
*** p < 0.001 indicate statistically significant difference between the HBO-treated cells and the control
group, respectively. ### and $$$ p < 0.001 indicate statistically significant difference between HB- and
HO-treated cells and control, respectively.
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Figure 4. Matrix mineralization in hADSCs after HBO treatment in the presence of inflammation.
(A) ARS staining and (B) quantification of calcium deposits in hADSCs after d1, d7, d14, and d21 of
culture in ODM supplemented with 10 ng/mL TNF-α and HBO, HB, or HO treatment. Scale bars
100 µm. Data are shown as mean ± SD. ** p < 0.01 and *** p < 0.001 indicate statistically significant
difference between the HBO-treated cells and the control group, respectively. ### p < 0.001 indicate
statistically significant difference between the HB-treated cells and control.
2.3. Effect of HBO on Pre-Committed hADSCs
Measurement of metabolic activity of hADSCs pre-differentiated for 10 days in ODM before
starting treatments revealed that HBO did not affect cell proliferation when compared to the untreated
condition at 14 and 21 days of culture; this was also true for cells subjected to the HB or HO treatments
alone (Figure 5A). Quantification of mineral calcium deposits by hADSCs pre-exposed to osteogenic
stimuli showed a considerable increment with culture time in all groups, without any difference
between treatments and control (Figure 5B,C).
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Figure 5. Metabolic activity and matrix mineralization of pre-committed hADSCs. (A) MTT assay
of hADSCs 14 and 21 days after osteogenic differentiation in ODM and HBO, HB, or HO treatment.
Data are shown as mean ± SD (n = 3). (B) ARS staining and (C), quantification of calcium deposits in
hADSCs after d14 and d21 of culture in ODM and HBO, HB, or HO treatment. Scale bars 200 µm. Data
are shown as mean ± SD (n = 3).
2.4. Effect of HBO on Expression of Osteogenic and Vasculogenic Markers by hADSCs
Real-time PCR was used to monitor the expression of key osteoblast regulators and bone matrix
proteins in hADSCs subjected to HBO-, HB-, or HO-treatment from the beginning of osteogenic
differentiation. Analyzed osteogenic markers included runt related transcription factor 2 (RUNX2),
osterix (OSX), alkaline phosphatase, liver/bone/kidney (ALP), osteocalcin (OCN), osteopontin (OPN),
and tumor necrosis factor (ligand) superfamily, member 11 (RANKL); gene expression of vascular
endothelial growth factor A (VEGFA) and kinase insert domain receptor (KDR) was additionally
evaluated (Figure 6). TFRC was chosen as reference gene for real-time PCR data normalization since its
expression resulted stable during MSCs osteogenic differentiation, as also established in our previous
works [23,24]. The levels of gene expression for the key transcription factor RUNX2 slightly increased
with culture time both in the treated and control groups, without significant differences between the
various conditions (Figure 6A). Expression of the other transcriptional regulator, OSX, was found to
be significantly (p < 0.001) reduced in the HBO-treated cultures as well as in the HO group at day 21
(Figure 6B). The expression of ALP, an early marker for osteogenic differentiation, peaked after 14 days
of culture in ODM in the untreated control cells, then it decreased at day 21 (Figure 6C). In contrast,
when hADSCs underwent the HBO treatment, ALP expression levels were significantly (p < 0.01) lower
than control on day 7, then they gradually increased over time, reaching the maximum after 21 days
of culture. ALP gene expression for the HB- and HO-treated groups trended the same as described
for the control cultures. The expression of the mineralization-specific genes OCN and OPN was
further evaluated. HBO, elevated pressure or elevated oxygen alone had no effect on OCN expression
compared to control until day 14; nevertheless, at day 21, OCN expression significantly decreased
in the HBO- and in the HO-treated groups (p < 0.01 and p < 0.001, respectively) when compared to
control (Figure 6D). The expression of the specific matrix protein OPN showed a gradual increase over
time in all cell cultures, but a significant (p < 0.01) down-regulation following treatment with HBO
and HB was observed at day 7 (Figure 6E). RANKL expression levels were not significantly different
at day 7 of differentiation for all the tested conditions, but noticeable differences were evidenced in
the course of culture time (Figure 6F). In particular, at day 14, HBO and HB significantly (p < 0.001)
increased RANKL expression when compared to control cultures, whereas elevated oxygen alone had
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no effect. Nevertheless, a significant (p < 0.001) down-regulation of RANKL expression was observed
for HBO and HO after 21 days of osteogenic differentiation. VEGFA expression was similar in the
control and treated groups during the first 14 days of culture; nevertheless, a significant (p < 0.05)
up-regulation was monitored in cells treated with HBO or HO at day 21 (Figure 6G). The expression of
the VEGFA receptor, KDR, significantly (p < 0.05) increased in HBO-treated cells at day 14; whereas it
was comparable and without any significant difference between the other tested conditions at any time
during culture (Figure 6H).
Figure 6. Gene expression profile of osteogenic and vasculogenic markers in hADSCs after HBO
treatment. Expression of the osteoblast lineage genes (A) RUNX2; (B) OSX; (C) ALP; (D) OCN; (E) OPN;
(F) RANKL; (G) VEGFA; and (H) KDR measured by real-time PCR. Data are expressed as mean ± SD
of the target gene versus reference gene (transferrin receptor, TFRC) ratio and represented by 2deltaCt.
*, $ p < 0.05, ##, ** p < 0.01, and ###, $$$, ***p < 0.001 mark significant changes in gene expression level
compared to the control within the same measurement day.
Gene expression of osteogenic and vasculogenic markers was additionally quantified in cell
cultures exposed to the pro-inflammatory cytokine TNF-α for all the duration of differentiation
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(Figure 7). The expression of RUNX2 showed a gradual increase with culture time both in the control
and treated groups, with a significant (p < 0.01) difference between HBO and control observed at day
7 (Figure 7A). Also OSX expression levels increased with culture time in all the tested conditions,
although a significant (p < 0.001) reduction was measured in the HBO- and HB-treated groups respect
to control at day 14 (Figure 7B). The expression of ALP and OCN increased in the HBO-treated group
as well as in the control over time, similarly to what observed in cells exposed to elevated pressure
or elevated oxygen alone (Figure 7C and 7D). The expression profile of OPN was comparable and
without any significant difference between the tested conditions at any time during culture (Figure 7E).
RANKL expression trended the same in the HBO- and HB-treated groups when compared to control
at each culture time; in contrast, a significant (p < 0.01) up-regulation in its transcriptional levels
was monitored in cells subjected to elevated oxygen alone at day 14 (Figure 7F). For both VEGFA
(Figure 7G) and KDR (Figure 7H), a significant (p < 0.01 and p < 0.05, respectively) up-regulation of
their expression levels was noted after 7 days of culture in HBO-treated cells.
Figure 7. Gene expression profile of osteogenic and vasculogenic markers in hADSCs after HBO
treatment in the presence of inflammation. Expression of (A) RUNX2; (B) OSX; (C) ALP; (D) OCN; (E)
OPN; (F) RANKL; (G) VEGFA; and (H) KDR measured by real-time PCR. Data are expressed as mean
± SD of the target gene versus reference gene (TFRC) ratio and represented by 2deltaCt. * p < 0.05, **,
$$ p < 0.01, and ***, ### p < 0.001 mark significant changes in gene expression level compared to the
control within the same measurement day.
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3. Discussion
A considerable number of studies have shown enhanced osteogenic activity on human osteoblasts
and bone marrow MSCs (BM-MSCs) as a result of HBO treatment [25–28]. In particular, it has
been reported that HBO promotes osteogenesis by stimulating osteoblast activity, neo-angiogenesis,
and increasing the accumulation of minerals needed for osteogenesis, such as calcium, magnesium,
and phosphorus [25,26,29]. To the best of our knowledge, the direct effects of the HBO therapy on
metabolic activity and osteogenic differentiation of hADSCs grown in a simulated pro-inflammatory
environment have not been investigated previously. In this study, hADSCs isolated from human
adipose tissue samples, then cultured and differentiated following the same protocol published in a
recent work from our laboratory, were used [23]. In that work, flow cytometric immunophenotypic
characterization showed that >99% of cells were positive for the MSCs-specific markers CD44, CD73,
CD90, and CD105, and simultaneously negative for the hematopoietic markers CD14, CD34, and
CD45. Once isolated, hADSCs were induced to osteogenic differentiation and contextually exposed
to HBO, HB or HO daily for 60 min, with the aim to replicate the duration of treatment received
by hyperbaric therapy patients [3]. Each treatment was carried out for 21 days, which is generally
considered an appropriate time period for in vitro evaluating the osteogenic differentiation properties
of hADSCs [30].
In human tissues, MSCs reside in an hypoxic microenvironment, containing oxygen tensions
ranging between 2% and 9%, which are considerably different from the inspired ambient oxygen levels
of 21% (160 mm Hg) [31]. This is because there is a distribution of oxygen tensions according to a
gradient [32]. As the inhaled air passes from the lungs to the circulation, the oxygen partial pressure
(pO2) progressively drops to about 14–65 mm Hg, depending on the target tissue, corresponding to the
mentioned levels of 2–9% O2 [31,33,34]. This also occurs at the cellular level [32]. It has been widely
demonstrated that such hypoxic conditions contribute to maintaining MSCs in an undifferentiated and
multipotent status [34–36]. Nonetheless, the osteogenic differentiation potential is found diminished
or even impaired when these cells are grown in hypoxic conditions [37–39]. During HBO treatment
(100% O2), the PaO2 in tissues rises to around 1500 mm Hg, which corresponds to pO2 of 500 mm
Hg in soft tissue and 200 mm Hg in bone [4]. It is well accepted that such exposure to high oxygen
concentrations increases the formation of reactive oxygen species (ROS), which in turn results in
consumption of antioxidants and reduction of antioxidant enzyme activity [40]. Furthermore, ROS
can react with macromolecular components, inducing cells necrosis or apoptosis [41]. However, the
effects generated by ROS can be either positive or negative, depending on their concentration and
intracellular localization [42]. Several studies have demonstrated that, since exposure to hyperoxia in
clinical HBO therapy is rather brief, cellular antioxidant defenses are adequate and biochemical stress
related to increased ROS is reversible [43,44]. More interestingly, it has been reported that the initial
oxidative stress induced by HBO therapy acts as a trigger mechanism stimulating antioxidative and
anti-inflammatory responses in cells [45].
In this work, measurements of the cell metabolic activity by means of the MTT assay revealed
that daily HBO treatment significantly decreases the rate of hADSCs proliferation both at 7 and
14 days respect to untreated control cells. Further quantification of DNA content confirmed a reduced
proliferation for the HBO-treated cells at 14 days. This difference disappeared by day 21, when all the
cell cultures reached confluence. MTT assay measurements are indicative of cell metabolism, since
the method is based on the reduction of a tetrazolium compound by mitochondrial dehydrogenase
enzymes present in metabolically active cells [46]. The reduction we observed at both 7 and 14 days in
HBO-treated hADSCs thus provides an indication of a decreased metabolic activity by cells, which in
turn could depend both on the reduction in cell number or on the reduction in the mitochondrial activity
per cell [47]. Nevertheless, this effect was neutralized at day 21, when hADSCs treated with HBO
showed metabolic activity comparable to control cells. Looking at the literature, variable responses of
HBO on cell proliferation have been reported [25,26]. In agreement with our results, the study of Wong
on primary human osteoblasts demonstrated that daily HBO treatments caused a 24% decrease in cell
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growth after 9 days in culture, through induction of apoptosis and cell cycle arrest [47]. In another
study, Lin and colleagues evaluated the role of HBO on the proliferation rate of BM-MSCs, induced or
not to the osteogenic lineage for up to 14 days [27]. Interestingly, the authors found that HBO increased
proliferation in osteogenically differentiated cells, whereas a decrease in cell proliferation following
HBO treatment was noted in uncommitted BM-MSCs. However, none of the studies published so far
evaluated the effect of HBO on hADSCs proliferation for 21 consecutive days. High pressure alone,
but not high oxygen alone, did not have any effect on cell metabolic activity, similarly to untreated
control cells.
The metabolic activity and proliferation of cells exposed to different pressure and oxygen signals
was additionally evaluated under in vitro simulated inflammatory conditions. The environment in
which MSCs reside, indeed, has been shown to influence the behavior and differentiation of these
cells, in addition to their regenerative capabilities [12]. In this regard, in all those situations where new
bone needs to be formed or repaired, for example as a result of damage, fracture, or around prosthetic
implants, the milieu contains many inflammatory cytokines, due to the concomitant damage and
host response to such damage [1]. In this work, inflammatory conditions were simulated in vitro by
supplementing the ODM with the pro-inflammatory cytokine TNF-α at a concentration of 10 ng/mL.
By comparing the growth rate of cells cultured in the presence or not of TNF-α within each condition,
a substantial increase in cell proliferation was recorded in the TNF-α-treated groups at days 14 and 21,
suggesting some mitogenic effects induced by the cytokine supplementation. The effect of TNF-α on
hMSCs proliferation is well documented in the literature, and it seems to be strongly dependent by its
concentration [48,49]. Bastidas-Coral and colleagues, for example, reported that TNF-α at a relatively
low concentration of 10 ng/mL increases hADSCs proliferation after 7 days of culture, suggesting
an important role of the cytokine during bone tissue repair [48]. In a previous study, Egea and
coworkers demonstrated that 50 ng/mL TNF-α for 7 days does not affect MSCs proliferation, whereas
lower dosages of the cytokine significantly stimulate MSCs proliferation, with a 2-fold increment at a
concentration of 5 ng/mL [49].
When hADSCs are treated with TNF-α and contextually exposed to HBO, HB or HO, comparable
growth rates with respect to the control condition were noted up to day 14. However, at day 21,
a significant reduction in cell metabolic activity, as revealed by MTT assay, and in cell proliferation,
measured in terms of DNA content, were observed in all the three treated groups. So far, no studies
evaluating the combinatorial effect of HBO and TNF-α on the metabolic activity of hADSCs have
been published. The only work that examined the simultaneous effect of these two parameters on cell
proliferation employed bone marrow-derived Endothelial Progenitor Cells, that were pre-exposed to
the cytokine incubation before applying HBO [50]. Overall, considering the results of MTT assay and
DNA content, the observed reduced cell proliferation following HBO treatment could be explained by
induction of cell death or cell cycle arrest through the generation of ROS [51]. As interestingly reviewed
by Chandel and Budinger, these increased ROS result in activation of Bcl-2 pro-apoptotic proteins,
which eventually lead to mitochondrial membrane permeabilization and cell death [52]. Nevertheless,
further investigations would be necessary for elucidating the exact mechanisms through which HBO
influences hADSCs growth.
The reduced proliferation rate at later time points can also be regarded as a sign of progression
in differentiation [53]. We therefore monitored the effects of the HBO treatment during hADSCs
osteogenesis by measuring calcium deposition in the extracellular matrix, which is considered as
one of the main parameters to assess osteogenic differentiation in vitro [54]. Matrix mineralization
begins a few days after the initial accumulation of osteoblast proteins, such as collagen and ALP, along
with calcium and phosphate deposition up to the late stage of mineralization [55]. The ARS staining
performed on treated and untreated cells confirmed the progression of osteogenic differentiation
from days 1 to 21. Nevertheless, quantification of the staining revealed a significant reduction in
mineral deposition in the HBO-, HB-, and HO-treated cells compared to the untreated control at day
21, indicating that pressure and oxygen signals somewhat interfere with the progression of hADSCs
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osteogenic differentiation. Our results are in contrast with those of Lin and colleagues, which reported
that HBO significantly increases calcium levels after 14 and 21 days of BM-MSCs osteogenic induction
compared to the control group [27,28]. The discrepancies among the present results and those reported
by Lin and coworkers may arise from the use of different cells (ADSCs versus BM-MSCs), different
treatment durations (60 min once daily versus 90 min every 36 h), and different calcium detection
methods (calcium mineral deposits versus free calcium ions). The trend was reversed in the presence of
inflammation, where cytokine supplementation associated to osteogenic factors determined a reduction
in mineral matrix deposition in untreated cells respect to control cells not exposed to TNF-α after 21
days of culture. In agreement with our results, the study of Bastidas-Coral and colleagues reported
that exposure of hADSCs to 10 ng/mL TNF-α decreases matrix mineralization compared to untreated
cells after 14 days of culture [48]. Despite several other works investigating the influence of TNF-α
on osteogenic differentiation of MSCs, its role still remains controversial. Indeed, both stimulatory
and inhibitory effects on MSCs osteoblastogenesis have been described for the pro-inflammatory
cytokine [54,56–59]. Most of these studies, however, agree on the fact that TNF-α influences the MSCs
osteogenic differentiation in relation to cytokine concentration, timing and duration of administration,
as well as to the cell types and species used [60–63]. Once again, no studies so far analyzed the
simultaneous effect of HBO and TNF-α on hADSCs osteogenesis.
The most relevant finding, however, is that, in the presence of prolonged inflammation,
the combination of elevated pressure and elevated oxygen was able to increase matrix mineralization
at levels higher than those seen in normobaric and normoxic controls. Notably, the increment in
extracellular calcium deposition was already evident after 14 days of culture. In contrast, daily treatments
with HB or HO alone did not have an effect on bone nodule formation, therefore being unable to
overcome the anti-osteogenic effect induced by persistent TNF-α supplementation. This observation is
of paramount importance if we consider that defective bone repair processes, such as delayed new
bone formation or excessive bone resorption, are often strictly associated to prolonged inflammatory
states [64,65]. These preliminary in vitro results, therefore, may indicate that HBO could be successfully
employed in all those conditions of inflammation-related bone loss. In line with this hypothesis, the
recent work of Bosco and colleagues demonstrated that two cycles of HBO therapy on 23 patients with
avascular necrosis of the femoral head resulted in a significant reduction of TNF-α and IL-6 plasma
levels over time, thus suggesting that HBO may have an anti-inflammatory activity [66].
In this study, we additionally investigated the effects of pressure and oxygen signals on
osteogenic-committed cells, with the aim to elucidate whether HBO could have a role in the course
of the hADSCs osteogenic differentiation process. For this purpose, hADSCs were pre-differentiated
for 10 days in ODM before starting the HBO, HB or HO treatments. This step produces cells that
are committed to the osteogenic lineage but not yet undergoing middle or late stages of osteoblastic
differentiation [67]. By comparing the data of this experimental scenario with those exposed so far, it is
possible to clarify if the pressure and oxygen signals have a greater influence on the undifferentiated
cells or on partially differentiated cells. Interestingly, at both 14 and 21 days of culture, HBO did not
affect cell proliferation and matrix mineralization of hADSCs pre-exposed to osteogenic stimuli when
compared to the untreated condition; this was also true for cells subjected to the HB or HO treatments
alone. We can therefore hypothesize that undifferentiated and osteogenically pre-committed cells
respond differently to pressure and oxygen signals, in particular under an inflammatory environment.
Our data would support the hypothesis that HBO, and its individual constituents, only affect the
behavior of cells uncommitted to the osteogenic lineage. On the contrary, high pressure and high
oxygen do not seem to influence the biological properties of hADSCs if already pre-committed to the
osteogenic phenotype. Remarkably, the increase in osteogenic differentiation observed in hADSCs
treated with HBO in the presence of pro-inflammatory mediators, accompanied by a reduction in cell
proliferation of these cells, would provide an indication of the potential application of HBO therapy in
all those inflammatory processes requiring bone regeneration.
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Besides phenotypic characteristics like extracellular matrix mineralization, the effect of the HBO
treatment was investigated at molecular level, by measuring the expression of genes that control proper
osteoblast differentiation and matrix mineralization. The gene expressions of several key markers were
quantified over 21 days to determine the influence of oxygen and pressure signals at different stages of
the hADSCs osteogenic differentiation process. The expression of the transcription factors RUNX2 and
OSX has been shown to be necessary for osteoblast differentiation at a relatively early stage, with OSX
acting downstream of RUNX2 [68,69]. RUNX2 is known to regulate the downstream expression of many
others phenotypic markers, among which are ALP, OCN, and OPN [70,71]. In control cells committed to
the osteogenic lineage, RUNX2 mRNA levels were stable from day 7 to day 21, whereas OSX expression
was low in the early stage but increased with time during differentiation, consistently with published
works [72,73]. In contrast, ALP expression reached the highest peak after 14 days of differentiation,
indicative of the osteogenic maturation process, then it decreased at day 21. In agreement with previous
studies, ALP gene expression has its maximum at around day 14 during osteogenic differentiation; then,
as the mineralization progresses, its expression undergoes a down-regulation due to the development
of an osteoid matrix around osteoblasts [67,74]. Starting from day 14, the osteogenic-differentiating
cells also began to express OCN, in agreement with the findings that OCN appears concomitantly with
the mineralization phase of bone formation [72]. Also the increment of OPN expression over time well
correlates with data available in the literature [53]. When hADSCs were exposed to HBO for all the
duration of differentiation, a certain reduction in the expression profile of some of the above described
markers was evidenced. For example, RUNX2 expression levels progressively increased throughout
the 21-day culture period, along with those of OCN and OPN. Nevertheless, these levels were greatly
lower than control at all time points of the experiment. In addition, the peak in ALP expression was
seen at day 21, thus suggesting that the combination of elevated pressure and elevated oxygen possibly
determines a delay in the osteogenic differentiation process of hADSCs. By contrast, when hADSCs
were HBO-treated after a 10-day osteogenic differentiation period, the analysis of gene expression on
the same markers did not show any differential change (data not shown), which would confirm the
MTT and ARS quantification data presented above.
Considering the stimuli individually, hyperoxia without pressure had a more similar effect to
HBO on hADSCs osteogenesis than HB alone. In fact, the expression profile of most of the genes
examined trended the same in the HBO- and HO-treated groups. Previous studies have shown that
changes in oxygen tension rather than in pressure directly impact on bone cell functions [75–77]. When
evaluating the expression profile of the osteogenic markers in cells exposed to in vitro simulated
inflammatory conditions, less pronounced differences between control and treated groups were seen.
These differences were mainly present at early stages of osteogenic differentiation, as in the case of
RUNX2, OSX and ALP, but disappeared at later time points. During bone formation, osteogenesis is
spatially and temporally coupled to the neovascularization process [78]. VEGF is involved in both
processes, being the most specific growth factor for neovascularization, and a downstream target
of OSX [79,80]. Its expression is low at the beginning of osteoblast differentiation, it increases in
parallel with OCN expression during terminal differentiation, then it peaks during mineralization [81].
Our results are in agreement with previous studies demonstrating that VEGF synthesis increases
following HBO treatment [79]. In particular, this increment was visible at the final stage of osteogenic
differentiation when cells were grown in ODM (day 21), and at earlier time points (day 7) in the
presence of inflammation. The increase in VEGFA expression was accompanied by up-regulation of
KDR, one of its two receptors [82,83].
Overall, these observations would strengthen the hypothesis that HBO is able to counteract the
anti-osteogenic effect induced by the cytokine supplementation. Looking at the literature, multiple
signaling pathways, including Transforming Growth Factor-β, Fibroblast Growth Factor, Hedgehog,
Ephrin, and sympathetic signaling pathways, are known to play important roles during osteogenic
differentiation of MSCs [72]. Among these, the canonical Wnt pathway (Wnt3a/β-catenin) appears to be
particularly important for bone biology, with RUNX2 being a direct target [84,85]. In the absence of a
Int. J. Mol. Sci. 2020, 21, 1452 14 of 22
Wnt ligand, cytoplasmic β-catenin is phosphorylated by glycogen synthase kinase 3β (GSK3β), and this
leads to its degradation via the ubiquitin/proteasome pathway [86]. Conversely, in the presence of Wnt
proteins, GSK3β is inhibited resulting in unphosphorylated β-catenin, which is therefore not degraded
and accumulates in the cytoplasm. Then, β-catenin enters the nucleus where it affects gene expression
through binding to transcription factors of the TCF/LEF family. It has been demonstrated that the
canonical Wnt pathway is modulated by oxygen availability in the cell microenvironment [87]. Also,
the binding of TNF-α to its receptors results in the activation of multiple signaling pathways, which
interact with each other to regulate the proliferation and differentiation of MSCs [62]. Interestingly,
some of the pathways activated by TNF-α are implicated in the phosphorilation of GSK3β. It has been
shown that GSK3β is required for TNF-α-mediated inhibition of osteogenic differentiation in MSCs [88].
In addition, TNF-α was found to suppress MSC osteogenesis through regulation of the Wnt signaling
pathway at different levels, including inhibition of β-catenin nuclear accumulation, decreased β-catenin
and reduced expression of Wnt proteins [58]. In the light of these considerations, further work could
involve, for example, the treatment of hADSCs with siRNA targeting molecules of the Wnt/β-catenin
pathway in the presence of high oxygen and/or TNF-α. In this way, it might be possible to unravel
whether the two stimuli share common molecular mediators, and to what extent.
4. Materials and Methods
4.1. Ethic Statement
Adipose tissue was obtained during abdominoplasty procedures from the abdominal region
of patients who had given written informed consent, according to the guidelines of the University
of Padova’s Plastic Surgery Clinic. All experiments were approved by the ethical committee of the
University of Padova (5 March 2009; 20150) and were conducted in accordance with the ethical
standards of the Helsinki Declaration.
4.2. Isolation and Culture of hADSCs
hADSCs were isolated from adipose tissue samples as published elsewhere [89]. Briefly, the fat
was washed with Phosphate Buffered Saline (PBS, EuroClone, Rome, Italy) and cut into small pieces.
The tissue was then digested with a solution of 0.075% Collagenase from Clostridium histolyticum Type
II (Sigma-Aldrich, Saint Louis, MA, USA) in Hank’s Balanced Salts Solution (HBSS, Lonza, Italy) and
placed under stirring for 3 h at room temperature. Collagenase’s activity was neutralized with an equal
volume of complete Dulbecco’s Modified Eagle Medium made by DMEM High Glucose (EuroClone),
10% Fetal Bovine Serum (FBS, EuroClone) and 1% Penicillin/Streptomycin (P/S, EuroClone), and
centrifuged at 260 × g for 4 min. The cell pellet was seeded in 75 cm2 cell culture flasks (Corning
Incorporated, Corning, New York, NY, USA) at a density of 5 × 103 cells/cm2 with cDMEM and
cultured at 37 ◦C and 5% CO2. At 80–90% confluence, cells were detached with trypsin-EDTA solution
(Sigma-Aldrich) and passaged repeatedly. hADSCs between passages 3 and 5 were used in this study.
4.3. Experimental Designs
An overview of the first experimental design is depicted in Figure 8. hADSCs were seeded in 24
Well Clear TC-Treated Multiple Well Plates (Corning Incorporated) at a density of 2 × 104 cells/cm2.
Cells were then cultured in the presence of ODM, which consisted of cDMEM supplemented with
10 nM dexamethasone (Sigma-Aldrich), 10 ng/mL Fibroblast Growth Factor 2 (ProSpec, East Brunswick,
NJ, USA), and 10 mM beta-glicerophosphate (Sigma-Aldrich). Contextually to the beginning of
differentiation, the cells were exposed daily for 60 min, and up to 21 days, to one of the following
treatments into appropriate designed chambers (Costruzioni Riunite Moro, CRM, Treviso, Italy)
prepared at the Hyperbaric Medicine Center (Padova, Italy) (Figure 8A): hyperbarism (2.4 ATA) and
hyperoxia (100% O2), in the text referred to as HBO; hyperbarism (2.4 ATA) and normoxia (21%
O2), indicated as HB; normobarism (0.97 ATA) and hyperoxia (100% O2), called HO (Figure 8B).
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The chambers were flushed twice with ambient air at up to 2 ATA for 10 min, before starting the
different treatment sessions. Cell incubations were performed at 37 ◦C and 5% CO2, with medium
changes every 3 days. In order to simulate a pro-inflammatory environment in vitro, ODM was
supplemented with 10 ng/mL of TNF-α (ProSpec); then, the cells were subjected to the same different
treatments as listed above (Figure 8C). TNF-α was freshly added in the medium at each change.
Untreated cells cultured in a standard humidified incubator at 37 ◦C containing 5% CO2, in the presence
of ODM with or without inflammation, represented the control condition (CTRL).
Figure 8. Schematic experimental design of treatments starting simultaneously with the osteogenic
differentiation of hADSCs. (A) Image of hyperbaric culture chamber used for HBO exposures.
(B) hADSCs are grown in ODM and contextually subjected to one of the following treatments: HBO,
HB, or HO. The control condition is represented by cells grown under normoxia and normobarism.
Each treatment is performed daily for a total of 21 days. (C) hADSCs are treated as described above
but in the presence of 10 ng/mL TNF-α. Tests for evaluating cell metabolic activity and osteogenic
differentiation, as evidenced in the legend, are performed at d1, d7, d14, and d21.
In the second experimental design, hADSCs (2× 104 cells/cm2) were pre-stimulated with osteogenic
factors for 10 days. Then, treatments with HBO, HB, or HO started from the tenth day to d21 of culture
(Figure 9).
Figure 9. Schematic experimental design of treatments starting after osteogenic pre-commitment of
hADSCs. hADSCs are pre-differentiated in ODM for 10 days (d10) before treatment with HBO, HB,
or HO. Each treatment is performed daily for 60 min from the tenth day to d21 of culture. Tests
for evaluating cell metabolic activity and osteogenic differentiation, as evidenced in the legend, are
performed at d14 and d21.
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4.4. MTT Assay
To determine the cell metabolic activity under the different experimental conditions, the MTT-based
viability assay was performed, as already published [90]. Briefly, after removing the culture medium
and washing with PBS, cells were incubated with 1 mL of 0.5 mg/mL MTT (Sigma-Aldrich) solution
prepared in PBS for 3 h at 37 ◦C. After removal of the MTT solution, 0.5 mL of 10% dimethyl sulfoxide
in isopropanol was added to extract the formazan in the samples for 10 min at 37 ◦C. For each sample,
Optical Density (O.D.) values at 570 nm were recorded in duplicate on 200 µL aliquots using a multilabel
plate reader (Victor 3, Perkin Elmer, Milan, Italy).
4.5. DNA Content
Total DNA was isolated from cells after 1 day, 7 days, 14 days and 21 days of culture using the
DNeasy Blood and Tissue kit (Qiagen, Hilden, Germany), following the manufacturer’s protocol for
tissue isolation, as published elsewhere [91]. The DNA concentration was measured with NanoDrop™
ND-1000 (Thermo Fisher Scientific, Waltham, MA, USA). Cell number was then extrapolated from
a standard curve, previously generated by relating the number of cells (increasing quantity) to the
corresponding DNA content.
4.6. ARS Staining and Quantification
ARS staining was used to reveal the ability of hADSCs to deposit a mineral matrix that is a
characteristic of osteoblastic lineage. Firstly, the cells were fixed with 10% formalin for 10 min at room
temperature. Cells were then washed twice with PBS, air dried, and stored at −20 ◦C till further use.
For ARS staining, cells were washed twice with double-distilled water (ddH2O) and incubated with
0.5 mL of 40 mM ARS solution (pH 4.2) for 20 min at room temperature with gentle shaking. After
removing the solution, cells were washed with ddH2O 4 times. Then cells were washed with PBS and
incubated with 0.5 mL of 10 mM CPC (Sigma-Aldrich) in 10 mM sodium phosphate solution (pH
7,0) for 20 min at room temperature with gentle agitation. 200 uL of the solution was transferred to
96-wells plate and measured at 570 nm in a plate reader.
4.7. Real-Time PCR
Total RNA was isolated after 7, 14, and 21 days of culture with the total RNA purification Plus
kit (Norgen Biotek, Thorold, ON, Canada). The RNA quality and concentration of the samples were
measured using the NanoDrop™ ND-1000 (Thermo Fisher Scientific). The cDNA was synthesized
following the SensiFAST™ cDNA Synthesis Kit (Bioline, Singapore). For each sample, 1000 ng of total
RNA was retrotranscribed in a reaction volume of 20 µL. Real-time PCR was then performed on a
Rotor-Gene 3000 (Corbett Research, Sydney, Australia). A total of 1.5 µL cDNA at the appropriate
dilution was added to the final reaction volume of 15 µL. The reaction contained 1× SensiFAST™
SYBR®No-ROX mix (Bioline), forward and reverse primer (400 nM each), and water. Human primers
were selected for each target gene with Primer 3 software (Table 1). The following PCR program was
used: 95 ◦C for 2 min, followed by 45 cycles of 95 ◦C for 5 s, 60 ◦C for 10 s and 72 ◦C for 20 s. Differences
in gene expression were calculated by normalizing to the expression of the transferrin receptor (TFRC)
housekeeping gene.
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Table 1. Human primer sequences.
Gene Name Forward Primer (5′ → 3′) Reverse Primer (5′ → 3′) Amplicon Size (bp)
ALP 1 GGCTTCTTCTTGCTGGTGGA CAAATGTGAAGACGTGGGAATGG 181
KDR 2 GGAGGAGGAGGAAGTATGTGACC AACCATACCACTGTCCGTCTG 184
OCN 3 GCAGCGAGGTAGTGAAGAGAC AGCAGAGCGACACCCTA 193
OPN 4 TGGAAAGCGAGGAGTTGAATGG GCTCATTGCTCTCATCATTGGC 192
OSX 5 TCAGAATCTCAGTTGATAGGGTTTCTC GGGTACATTCCAGTCCTTCTCC 183
RANKL 6 TCAGCATCGAGGTCTCCAAC CCATGCCTCTTAGTAGTCTCACA 194
RUNX2 7 AGCCTTACCAAACAACACAACAG CCATATGTCCTCTCAGCTCAGC 175
TFRC 8 TGTTTGTCATAGGGCAGTTGGAA ACACCCGAACCAGGAATCTC 222
VEGFA 9 GGACAGAAAGACAGATCACAGGTAC GCAGGTGAGAGTAAGCGAAGG 182
1 alkaline phosphatase, liver/bone/kidney; 2 kinase insert domain receptor; 3 osteocalcin; 4 osteopontin; 5 osterix;
6 tumor necrosis factor (ligand) superfamily, member 11; 7 runt related transcription factor 2; 8 transferrin receptor;
9 vascular endothelia growth factor A.
4.8. Statistical Analysis
Each experiment was performed independently three times in triplicate. Statistical calculations
were performed using GraphPad software (La Jolla, CA, USA). The mean values for quantitative data
were compared applying non-parametric Kruskal-Wallis test for MTT and ARS assays results as well
as for DNA content measurements. Real-time PCR data were analyzed using Student’s unpaired t-test
based on 2deltaCt values for each gene of the test group compared with that of the control group.
Significance levels were calculated in comparison to the control condition and indicated as follows:
p < 0.05, p < 0.01, p < 0.001.
5. Conclusions
In conclusion, the results of our work demonstrate that hADSCs respond differently to pressure
and oxygen signals in the course of the osteogenic differentiation process. HBO, and its individual
constituents, elevated pressure and elevated oxygen, do not affect the metabolic activity and the
osteogenic properties of hADSCs if cells are pre-committed to the osteogenic lineage. On the contrary,
when the HBO treatment starts contextually to the osteogenic differentiation of the cells, a decrease in
cell proliferation is observed in the middle stages of culture, together with a reduction in extracellular
calcium deposition and expression of osteogenic markers at later time points. High oxygen alone
shows effects comparable to HBO, although less pronounced, whereas high pressure alone has no
effect, similarly to untreated control cells. Our results also reveal that constant exposure to the
pro-inflammatory cytokine TNF-α clearly inhibits hADSCs osteogenesis. Nevertheless, if prolonged
inflammation is combined with high pressure and high oxygen stimuli, enhanced mineral deposition
and expression of osteogenic markers by hADSCs are displayed at later time points. This effect is not
observed in cells exposed to HB or HO alone. Considering that prolonged inflammatory states, which
are typical of several bone disorders, have destructive effects on bone tissue formation, resolution of
inflammation through HBO therapy might be beneficial for hADSCs osteogenesis. Although further
studies are necessary, the findings of the present work would suggest that HBO could have a promising
future as an adjunctive therapeutic approach for treating many challenges cases of inflammation-related
bone loss.
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